National Research Corporation Announces Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
National Research Corporation Announces Third Quarter 2014 Results

LINCOLN, Neb., Nov. 4, 2014 (GLOBE NEWSWIRE) -- National Research Corporation (Nasdaq: NRCIA ) (Nasdaq: NRCIB ) today announced results for the third quarter of 2014.

  • Net New Sales $8.1 million, up 30%
  • Total Contract Value $103.2 million
  • Revenue up 6% to $23.7 million
  • Net Income of $4.6 million, up 19%

Remarking on Company performance, Michael D. Hays, chief executive officer of National Research said, "Net new sales continue to register impressive gains across the product portfolio. Of particular note is our Market Insights product, which achieved a 48% year-to-date sales growth driven by the growing importance of branding."

Revenue for the quarter ended September 30, 2014, was $23.7 million, compared to $22.4 million for the same quarter in 2013. Net income for the quarter ended September 30, 2014, was $4.6 million, compared to $3.8 million for the quarter ended September 30, 2013. Diluted earnings per share increased to $0.11 for Class A shares and $0.64 for Class B shares for the quarter ended September 30, 2014, from diluted earnings per share of $0.09 for Class A shares and $0.54 for Class B shares for the quarter ended September 30, 2013. Combined diluted earnings per share (a non-GAAP measure) increased to $0.19 for the quarter ended September 30, 2014, from $0.15 for the third quarter of 2013.

Regarding third quarter performance, Kevin Karas, chief financial officer of National Research said, "The record net new sales performance positions the company to generate increased organic revenue growth rates into the fourth quarter of this year and the year 2015 . From an earnings standpoint, we continue to enjoy leverage on incremental revenue which resulted in net income growth of 19% for the quarter."

In October, National Research made investments in two strategic technologies to advance the company's commitment to empowering consumer-centric healthcare across the continuum.  The first, an asset purchase, creates a Center of Excellence in Atlanta, Georgia, responsible for developing novel solutions to enhance consumer decision-making in the selection of healthcare providers.  The second, a seed investment, creates an option for a later acquisition of a partner company that has developed a talent-matching solution to accelerate the formation of high-performing teams.  Both solutions will be launched to market in 2015.

A listen-only simulcast of the National Research 2014 third quarter conference call will be available online at http://www.media-server.com/m/p/boqud8ua on November 5, 2014, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.

For more than 33 years, National Research Corporation has been at the forefront of patient-centered care, helping healthcare providers measure and improve quality and services through analytics that offer a rich understanding of customers' experiences, preferences, risks and behaviors across the healthcare continuum.

The information discussed within this release includes financial results and projections that are in accordance with accounting principles generally accepted in the United States (GAAP). In addition, certain non-GAAP financial measures have been provided that calculate combined earnings per share based on combined Class A and Class B shares and share equivalents outstanding, respectively. The non-GAAP measures should be read in conjunction with the corresponding GAAP measures and should be considered in addition to, and not as an alternative or substitute for, the measures prepared in accordance with GAAP. Please note that the Company's non-GAAP measures may be different than those used by other companies. The additional non-GAAP financial information the Company presents should be considered in conjunction with, and not as a substitute for, the Company's financial information presented in accordance with GAAP. The non-GAAP financial measures are provided in an effort to provide information that investors may deem relevant to evaluate results from the company's core business operations and to compare the company's performance with prior periods. The company uses both GAAP and these non-GAAP financial measures for evaluating comparable financial performance against prior periods. 

This press release includes "forward-looking" statements related to the Company that can generally be identified as describing the Company's future plans, objectives or goals. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For further information about the factors that could affect the Company's future results, please see the Company's filings with the Securities and Exchange Commission.

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)
         
  Three months ended
September 30,  
Nine months ended
September 30,     
  2014   2013  2014  2013 
         
Revenue $ 23,682 $ 22,407 $ 73,713 $ 69,667
         
Operating expenses:        
Direct  9,769 9,452 30,871 29,196
Selling, general and administrative 5,805 6,019 18,154 18,903
Depreciation and amortization 949 907 2,810 2,788
Total operating expenses 16,523 16,378 51,835 50,887
         
Operating income 7,159 6,029 21,878 18,780
         
Other income (expense):        
Interest income 22 14 58 45
Interest expense (76) (91) (236) (309)
Other, net 2 (4) 16 28
         
Total other expense (52) (81) (162) (236)
         
Income before income taxes 7,107 5,948 21,716 18,544
         
Provision for income taxes 2,555 2,135 7,659 6,827
         
Net income  $ 4,552 $ 3,813 $ 14,057 $ 11,717
         
Earnings Per Share of Common Stock:        
Basic Earnings Per Share:        
Class A $ 0.11 $ 0.09 $ 0.34 $ 0.28
Class B  $ 0.66 $ 0.55 $ 2.03 $ 1.70
Diluted Earnings Per Share:        
Class A  $ 0.11 $ 0.09 $ 0.33 $ 0.28
Class B  $ 0.64 $ 0.54 $ 1.99 $ 1.67
         
Weighted average shares and share equivalents outstanding        
Class A - basic 20,771 20,672 20,761 20,671
Class B - basic 3,474 3,445 3,472 3,445
Class A - diluted 21,035 21,111 21,078 21,087
Class B - diluted 3,536 3,514 3,538 3,513
 
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except per share amounts and par value)
     
  Sep. 30,
2014
Dec. 31,
2013
ASSETS    
Current Assets:    
Cash and cash equivalents  $ 39,063  $ 22,092
Accounts receivable, net 10,924 11,043
Income taxes receivable 156 357
Other current assets 3,059 3,074
Total current assets 53,202 36,566
     
Property and equipment, net 11,943 11,898
Goodwill 57,475 57,593
Other, net 4,443 5,031
Total Assets  $ 127,063  $ 111,088
     
LIABILITIES AND SHAREHOLDERS' EQUITY    
     
Current Liabilities:    
Accounts payable and accrued expenses  $ 3,498  $ 3,230
Deferred revenue 16,983 13,885
Accrued compensation 4,084 4,319
Income taxes payable 112 92
Notes payable 2,310 2,256
Total Current Liabilities 26,987 23,782
     
Non-current liabilities 13,768 15,551
     
Total Liabilities 40,755 39,333
     
Shareholders' Equity:    
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued -- --
Class A Common stock, $0.001 par value; authorized 60,000,000 shares, issued 25,372,186 in 2014 and 25,285,029 in 2013, outstanding 20,808,304 in 2014 and 20,768,784 in 2013  25 25
Class B Common stock, $0.001 par value; authorized 80,000,000 shares, issued 4,234,643 in 2014 and 4,220,117 in 2013, outstanding 3,480,217 in 2014 and 3,467,410 in 2013 4 4
Additional paid-in capital 44,127 42,192
Retained earnings 72,099 58,042
Accumulated other comprehensive income (loss) (231) 302
Treasury stock (29,716) (28,810)
Total shareholder's equity 86,308 71,755
Total liabilities and shareholders' equity  $ 127,063  $ 111,088
 
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Non-GAAP Combined Earnings Per Share Schedule
(In thousands, except per share data)
         
  Three months ended 
September 30,  
Nine months ended
September 30,     
    2014    2013   2014   2013 
         
         
Combined Earnings Per Share         
Basic Earnings Per Share  $ 0.19 $ 0.16 $ 0.58 $ 0.49
Diluted Earnings Per Share $ 0.19 $ 0.15 $ 0.57 $ 0.48
         
Combined weighted average shares and share equivalents outstanding        
Combined - Basic 24,245 24,117 24,234 24,116
Combined - Diluted 24,571 24,625 24,617 24,600

Kevin R. Karas Chief Financial Officer 402-475-2525

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading